Clinical TrialJun 1, 2026, 09:02 AM
Alpha Tau Alpha DaRT shows 11.2-month mOS in pancreatic cancer
AI Summary
Alpha Tau Medical announced positive overall survival and safety results from a pooled analysis of three Phase I/II clinical studies for its Alpha DaRT therapy in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). The treatment demonstrated encouraging median overall survival (mOS) across various patient populations, including 11.2 months for metastatic patients after 1st line chemotherapy, compared to historical ~4-6 months. A favorable safety profile was observed with 36% treatment-associated adverse events and 9% Grade ≥3 events, all resolved, with no treatment-related deaths. The company is now focused on completing recruitment for its U.S. IMPACT pancreatic cancer trial.
Key Highlights
- Alpha DaRT achieved 11.2 months median overall survival (mOS) in metastatic PDAC patients after 1st line chemotherapy.
- This compares to ~4-6 months mOS for metastatic patients with second-line chemotherapy in historical data.
- Locally advanced patients after 1st line chemotherapy achieved 11.1 months mOS vs. ~9 months historically.
- Heavily pretreated patients (two prior lines) achieved 11.3 months mOS in metastatic disease.
- Treatment-associated adverse events were observed in 36% of subjects.
- Grade ≥3 adverse events were observed in 9% of subjects; all resolved with no treatment-related deaths.
- Company is completing recruitment for the multicenter U.S. IMPACT pancreatic cancer trial.
Price Impact
More from DRTS